1-6 of 6
Ana Tari
Close
Sort by
Journal Articles

Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML)

Maro Ohanian, Tara L. Lin, Ellen Ritchie, Michael Craig, Apurv Agrawal, Kathleen G. Halka, Naveen Pemmaraju, Gautam Borthakur, Miranda Lim, Sherry A. Pierce, Ana Tari Ashizawa, Hagop Kantarjian, Jorge E. Cortes, Gail J. Roboz
Journal: Blood
Blood (2021) 138 (Supplement 1): 1281.
https://doi.org/10.1182/blood-2021-152750
Published: 2021
Journal Articles

Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML)

Maro N. Ohanian, DO, Tara L Lin, MD, Ellen K. Ritchie, MD, Michael Craig, MD, Apurv Agrawal, MD, Kathleen G. Halka, MD, Vinit Karur, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Sarah Aminov, Miranda Lim, BSN, Sherry A. Pierce, BSN, BA, Natalie Sacarakis, Stacy Minor, Ana Tari Ashizawa, PhD, William Hahne, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1387.
https://doi.org/10.1182/blood-2018-99-113693
Published: 2018
Journal Articles

BP1001, a Novel Therapeutic for Chronic Myelogenous Leukemia

Ana Tari Ashizawa, PhD, Maro Ohanian, DO, Jorge E. Cortes, MD
Journal: Blood
Blood (2016) 128 (22): 4239.
https://doi.org/10.1182/blood.V128.22.4239.4239
Published: 2016
Journal Articles

Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Elias Jabbour, Marina Konopleva, MD PhD, Miranda Lim, BSN, Sherry Pierce, BSN, BA, Susan O'Brien, MD, Bradley G. Somer, MD, Ana Tari, PhD, William Wierda, MD PhD, Srdan Verstovsek, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2015) 126 (23): 3801.
https://doi.org/10.1182/blood.V126.23.3801.3801
Published: 2015
Journal Articles

Safety, Pharmacokinetics, and Efficacy Of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) In Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD, PhD, Elias Jabbour, MD, Marina Konopleva, MD, PhD, Susan O'Brien, MD, Alfonso Quintas-Cardama, MD, Bradley G. Somer, MD, Ana Tari, PhD, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2013) 122 (21): 2679.
https://doi.org/10.1182/blood.V122.21.2679.2679
Published: 2013
Journal Articles

Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia

Brief Report
Michele Milella, Zeev Estrov, Steven M. Kornblau, Bing Z. Carter, Marina Konopleva, Ana Tari, Wendy D. Schober, David Harris, Clinton E. Leysath, Gabriel Lopez-Berestein, Ziwei Huang, Michael Andreeff
Journal: Blood
Blood (2002) 99 (9): 3461–3464.
https://doi.org/10.1182/blood.V99.9.3461
Published: 2002